Cumulus Neuroscience raises $4.4M — develops wireless dry-EEG for clinical trials and cognition assessment
Summary
Belfast-based Cumulus Neuroscience raised $4.4M from existing investors to advance their wireless dry-electrode EEG headset and AI neurocognitive assessment platform targeting pharmaceutical clinical trials. Cumulus' system enables objective cognitive biomarker measurement outside the clinic, and their Phase 1 Nature publication demonstrated visual evoked potential modulation assessment in a clinical setting.
Why it matters
Cumulus represents the under-covered segment of neurotech — small, focused companies building the EEG measurement infrastructure that pharmaceutical companies need to run cognitive endpoints in CNS trials. Their Nature publication at Phase 1 scale demonstrates credibility that will attract pharma partnerships.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial